Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,361 shares of the medical equipment provider’s stock after selling 1,076 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Hologic were worth $393,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. Dark Forest Capital Management LP lifted its holdings in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider’s stock worth $220,000 after buying an additional 223 shares during the last quarter. Baker Avenue Asset Management LP lifted its holdings in Hologic by 0.5% during the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider’s stock worth $3,031,000 after buying an additional 225 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Finally, Integrated Advisors Network LLC lifted its holdings in shares of Hologic by 5.4% in the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 289 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.9%

HOLX opened at $64.74 on Monday. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The stock’s fifty day moving average is $60.71 and its 200-day moving average is $63.65. The company has a market capitalization of $14.43 billion, a PE ratio of 27.31, a P/E/G ratio of 2.37 and a beta of 0.55.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.03 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Evercore ISI cut their price target on Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Raymond James Financial reissued an “outperform” rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Finally, Stephens cut their price target on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, May 13th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Hold” and a consensus price target of $77.42.

Insider Activity

In related news, Director Martin D. Madaus bought 5,445 shares of the firm’s stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director directly owned 5,445 shares of the company’s stock, valued at $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.88% of the stock is owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.